Field Safety Corrective Action (FSCA)

What is a field safety corrective action?

A field safety corrective action, or FSCA, is action taken by a medical device manufacturer for technical or medical reasons to prevent or reduce the risk of a serious incident involving a device already made available on the market. This definition appears in Article 2(68) of the EU Medical Device Regulation.

An FSCA can involve returning, exchanging, modifying or destroying affected devices. It can also involve a software update, revised instructions, additional user training or new advice about how a device should be used or monitored. The appropriate action depends on the risk, the affected population and where the devices have been distributed.

Is an FSCA the same as a medical device recall?

Not always. A recall is one possible type of FSCA, but an FSCA does not necessarily require every affected device to be returned. A risk may be controlled through an on-site correction, software patch, inspection or updated instructions.

An FSCA is also different from a field safety notice. The FSCA is the corrective action itself; the field safety notice is the communication sent to users or customers explaining the issue and required action. The European Commission’s MDCG 2023-3 rev.2 provides current guidance on these vigilance concepts.

When must an FSCA be reported?

Manufacturers must assess potential safety issues promptly and follow the reporting rules of every jurisdiction in which affected devices were supplied. Under the EU MDR, reportable FSCAs are notified to the relevant competent authorities, and users receive a field safety notice. Great Britain has a related but separate process under the MHRA vigilance requirements.

Reporting thresholds, forms and timelines vary by market. A single global action therefore needs a coordinated regulatory strategy rather than one report reused unchanged everywhere.

Who is responsible for managing an FSCA?

The manufacturer remains responsible for the investigation, risk evaluation, regulatory communication, corrective action and effectiveness checks. Authorized representatives, importers and distributors can support communication and traceability, but they do not remove the manufacturer’s responsibility.

For EU-specific reporting and post-market processes, see our EU MDR and IVDR post-market surveillance guide. Manufacturers supplying Great Britain should also review the United Kingdom medical device market requirements.